For others, it may be a bit more quotidian. And if we want low-propensity voters to begin building the habit, we have to ...
In a propensity-matched comparison of two CAR T-cell therapies, ciltacabtagene autoleucel (cilta-cel, Carvykti) demonstrated better efficacy than idecabtagene vicleucel (ide-cel, Abecma) for ...
The Artstor website will be retired on Aug 1st. Journal of Transport and Land Use Vol. 10, No. 1, 2017 The Propensity to Cycle Tool: An open so... Abstract: Getting people cycling is an increasingly ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- In a propensity-matched comparison of two CAR T-cell therapies, ciltacabtagene autoleucel (cilta-cel ...